Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

CXCL12 Inhibition By Nox-A12 (Olaptesed Pegol) Synergizes with the ADCC Activity of CD20 Antibodies By Increasing NK Cell Infiltration in a 3D Lymphoma Model

Dirk Zboralski, Anna Kruschinski, Axel Vater

Blood (2016) 128 (22): 3021.

https://doi.org/10.1182/blood.V128.22.3021.3021

Published: 2016

Journal Articles

Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma

Heinz Ludwig, Univ. Prof. Dr., Katja Weisel, MD, Maria Teresa Petrucci, MD, Xavier Leleu, MD, Anna Maria Cafro, MD, Garderet Laurent, MD, Niklas Zojer, MD, Robin Foa, MD, Richard Greil, MD, Ibrahim Yakoub-Agha, MD PhD, Anna Kruschinski, PhD, Thomas Dümmler, PhD, Kai Riecke, MD, Monika Engelhardt, MD

Blood (2014) 124 (21): 2111.

https://doi.org/10.1182/blood.V124.21.2111.2111

Published: 2014

Journal Articles

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Michael Steurer, MD, Marco Montillo, MD, Lydia Scarfò, Francesca Romana Mauro, Johannes Andel, MD, Sophie Wildner, MD, Livio Trentin, MD, Ann Janssens, MD, Sonja Burgstaller, MD, Anna Kruschinski, PhD, Thomas Dümmler, PhD, Kai Riecke, MD, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Marco Gobbi, MD

Blood (2014) 124 (21): 1996.

https://doi.org/10.1182/blood.V124.21.1996.1996

Published: 2014

Journal Articles

Comparison of Ibrutinib, Idelalisib and Olaptesed Pegol on the Immune Effector Function Mediated By Rituximab

Dirk Zboralski, PhD, Axel Vater, PhD, Anna Kruschinski, PhD

Blood (2014) 124 (21): 4499.

https://doi.org/10.1182/blood.V124.21.4499.4499

Published: 2014

Journal Articles

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

Julia Hoellenriegel, Dirk Zboralski, Christian Maasch, Nathalie Y. Rosin, William G. Wierda, Michael J. Keating, Anna Kruschinski, Jan A. Burger

Blood (2014) 123 (7): 1032–1039.

https://doi.org/10.1182/blood-2013-03-493924

Published: 2014

Includes: Supplemental data

Journal Articles

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study

Heinz Ludwig, MD, Katja Weisel, MD, Monika Engelhardt, MD, Richard Greil, MD, Anna Maria Cafro, MD, Maria Teresa Petrucci, MD, Thomas Dümmler, PhD, Stefan Zöllner, PhD, Stefan Zeitler, MD, Kai Riecke, MD, Anna Kruschinski, PhD

Blood (2013) 122 (21): 1951.

https://doi.org/10.1182/blood.V122.21.1951.1951

Published: 2013

Journal Articles

SDF-1 Inhibition Using Spiegelmer ® Nox-A12 As a Novel Strategy For Targeting AML Cells Within Their BM Microenvironment

Rodrigo Jacamo, PhD, Zhihong Zeng, MD, Ye Chen, PhD, Yuexi Shi, Teresa McQueen, BS, Anna Kruschinski, PhD, Marina Konopleva, MD, PhD, Peter P. Ruvolo, PhD, Michael Andreeff, MD, PhD

Blood (2013) 122 (21): 2454.

https://doi.org/10.1182/blood.V122.21.2454.2454

Published: 2013

Journal Articles

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Marco Gobbi, MD, Michael Steurer, MD, Federico Caligaris-Cappio, MD, Marco Montillo, MD, Ann Janssens, MD, Livio Trentin, MD, Thomas Dümmler, PhD, Stefan Zöllner, PhD, Stefan Zeitler, MD, Kai Riecke, MD, Anna Kruschinski, PhD

Blood (2013) 122 (21): 1635.

https://doi.org/10.1182/blood.V122.21.1635.1635

Published: 2013

Journal Articles

The Spiegelmer ® Nox-A12 Abrogates Homing Of Human CLL Cells To Bone Marrow and Mobilizes Murine CLL Cells In The Eμ-TCL1 Transgenic Mouse Model Of CLL

Elisabeth Hinterseer, Tamara Girbl, Evelyn Hutterer, Petra Berghammer, Sylvia Ganghammer, Eveline Sifft, Josefina Pinon Hofbauer, Alexander Egle, Anna Kruschinski, PhD, Richard Greil, MD, Tanja Nicole Hartmann

Blood (2013) 122 (21): 4111.

https://doi.org/10.1182/blood.V122.21.4111.4111

Published: 2013

Journal Articles

Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer ® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization

Dirk Zboralski, PhD, Julia Hoellenriegel, Christian Maasch, PhD, Anna Kruschinski, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 318.

https://doi.org/10.1182/blood.V120.21.318.318

Published: 2012

Journal Articles

Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)

Marco Gobbi, MD, Federico Caligaris-Cappio, MD, Marco Montillo, MD, Stephanie Vauléon, PhD, Stefan Zöllner, PhD, Thomas Dümmler, PhD, Anna Kruschinski, PhD, Frank Fliegert, MD

Blood (2012) 120 (21): 4593.

https://doi.org/10.1182/blood.V120.21.4593.4593

Published: 2012

Journal Articles

In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches

Aldo M. Roccaro, MD, PhD, Antonio Sacco, BS, Marco Ungari, MD, Patricia Maiso, PhD, Salomon Manier, MD, Phong Quang, BS, Yosra Aljaway, BS, Dirk Zboralski, PhD, Anna Kruschinski, PhD, Fabio Facchetti, MD, Giuseppe Rossi, MD, Irene M. Ghobrial, MD

Blood (2012) 120 (21): 440.

https://doi.org/10.1182/blood.V120.21.440.440

Published: 2012

Journal Articles

L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (Nox-A12) Disrupts the Interaction of Multiple Myeloma Cells with the Bone Marrow Milieu In Vivo , Leading to Enhanced Sensitivity to Bortezomib

Aldo M Roccaro, MD, PhD, Antonio Sacco, BS, Phong Quang, BS, AbdelKareem Azab, PhD, Patricia Maiso, PhD, Feda Azab, BPharm, Yong Zhang, PhD, Ghayas C Issa, MD, Yang Liu, PhD, Hai T Ngo, BS, Anna Kruschinski, PhD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 887.

https://doi.org/10.1182/blood.V118.21.887.887

Published: 2011

Journal Articles

The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,

Julia Hoellenriegel, Dirk Zboralski, PhD, Zeev Estrov, William G. Wierda, MD, PhD, Michael Keating, MD, Anna Kruschinski, PhD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 3878.

https://doi.org/10.1182/blood.V118.21.3878.3878

Published: 2011

NARROW

CXCL12 Inhibition By Nox-A12 (Olaptesed Pegol) Synergizes with the ADCC Activity of CD20 Antibodies By Increasing NK Cell Infiltration in a 3D Lymphoma Model

Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia

Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Comparison of Ibrutinib, Idelalisib and Olaptesed Pegol on the Immune Effector Function Mediated By Rituximab

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study

SDF-1 Inhibition Using Spiegelmer ® Nox-A12 As a Novel Strategy For Targeting AML Cells Within Their BM Microenvironment

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

The Spiegelmer ® Nox-A12 Abrogates Homing Of Human CLL Cells To Bone Marrow and Mobilizes Murine CLL Cells In The Eμ-TCL1 Transgenic Mouse Model Of CLL

Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer ® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization

Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)

In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches

L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (Nox-A12) Disrupts the Interaction of Multiple Myeloma Cells with the Bone Marrow Milieu In Vivo , Leading to Enhanced Sensitivity to Bortezomib

The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only